Gateway 2011: Jost Chemical Co - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2011: Jost Chemical Co


Your online Gateway to Jost Chemical Co. in 2011

"Quality Delivered On-Time"

8150 Lackland
St. Louis, MO   63114
Phone: +1.314.428.4300
Fax: +1.314.428.4366
www.jostchemical.com

For over 25 years Jost Chemical Co. has manufactured high purity specialty chemicals for the pharmaceutical, nutritional, food and reagent market. Jost’s St. Louis, MO site, comprised of two manufacturing buildings totaling 190,000 ft2, is FDA registered and operates under ICH Q7 bulk pharmaceutical cGMP’s. Our 250+ high purity chemical salts are manufactured to meet USP/EP/BP/JP/ACS/FCC and multi-compendia requirements and are BSE/TSE free and allergen free. By continually focusing on product quality through controlled validated processes and lot-to-lot product consistency, Jost is able to meet specific product requirements and if required can develop a DMF, ASMF and CEP. Packaging options include fiber drums, poly drums, poly pails, cartons, super sacks, etc. Custom packaging is also available. Please visit Jost’s website at www.jostchemical.com to access information on product specifications, MSDS’s and various product certifications.


Visit our Stand: Number FOD10


We look forward to meeting with you at the 2011 CPhI Exhibition in Frankfurt, Germany to discuss how Jost Chemical can assist in your drug development projects. Please contact Jeff Lenger, Director of Sales and Marketing, to arrange a meeting at CPhI. Jeff can be contacted at jeff.lenger@jostchemical.com

 

Jost Lab

New Products
and Releases
New Whitepapers

Coming soon!

Coming soon!



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here